IP Library Granted Patent US 7,863,314
Granted Patent B2
US 7,863,314 · App. 10/877,534 · Granted Jan 4, 2011

5-membered heterocycle-based p38 kinase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,863,314
App. No.
10/877,534
Granted
Jan 4, 2011
Kind
B2
Abstract

Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

Claims (12)

1. A compound or pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methyl-benzamide;

3-[5-amino-4-(3-iodo-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide;

3-[5-amino-4-(3-hydroxymethyl-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide;

3-[5-amino-4-(3-hydroxy-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide; and

3-[5-amino-4-(4-methyl-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide.

2. The compound of claim 1 which compound is 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 which compound is 3-[5-amino-4-(3-iodo-benzoyl)-pyrazol-1-yl]N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 which compound is 3-[5-amino-4-(3-hydroxymethyl-benzoyl)-pyrazol-1-yl]N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 which compound is 3-[5-amino-4-(3-hydroxy-benzoyl)-pyrazol-1-yl]N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 which compound is, 3-[5-amino-4-(4-methyl-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt thereof.

7. 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jan 23, 2021
From: KREOS CAPITAL V (UK) LIMITED
To: MEREO BIOPHARMA 1 LIMINTED
Reel/Frame 055010/0654 →
SECURITY INTEREST Recorded Nov 7, 2018
From: MEREO BIOPHARMA 1 LIMITED
To: KREOS CAPITAL V (UK) LIMITED
Reel/Frame 047446/0556 →
CHANGE OF ADDRESS Recorded May 23, 2018
From: MEREO BIOPHARMA 1 LIMITED
To: MEREO BIOPHARMA 1 LIMITED
Reel/Frame 046223/0457 →
SECURITY INTEREST Recorded Aug 10, 2017
From: MEREO BIOPHARMA 1 LIMITED
To: KREOS CAPITAL V (UK) LIMITED
Reel/Frame 043523/0317 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2015
From: NOVARTIS AG
To: NOVARTIS PHARMA AG
Reel/Frame 036952/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2015
From: NOVARTIS PHARMA AG
To: MEREO BIOPHARMA 1 LIMITED
Reel/Frame 036695/0602 →